Francesco Fiorica*, Maria Colella, Rosaria Taibi, Andrea Bonetti, Jacopo Giuliani, Maria Sole Perrone, Sonia Missiroli and Carlotta Giorgi Pages 2814 - 2825 ( 12 )
<P>Glioblastoma multiforme (GBM) is characterized by poor prognosis despite an aggressive therapeutic strategy. In recent years, many advances have been achieved in the field of glioblastoma biology. <P> Here we try to summarize the main clinical and biological factors impacting clinical prognostication and therapy of GBM patients. From that standpoint, hopefully, in the near future, personalized therapies will be available.</P>
Glioblastoma, prognostic factor, predictive response, Glioblastoma multiforme (GBM).
Department of Radiation Oncology, AULSS 9 Scaligera, Verona, Department of Radiation Oncology, University Hospital Ferrara, Ferrara, Department of Medical Oncology, National Cancer Institute, Aviano (PN), Department of Oncology, AULSS 9 Scaligera, Verona, Department of Oncology, AULSS 9 Scaligera, Verona, Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara